Fulltext

Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis

Jaiswal V 1 , Peng Ang S 2 , Sarfraz Z 3 , Butey S 4 , Vinod Khandait H 5 , Song D 6 Show all authors , Ee Chia J 7 , Maroo D 8 , Hanif M 9 , Ghanim M 10 , Chand R 5 , Biswas M 11

Affiliations 

  • 1 AMA School Of Medicine, Makati, Philippines
  • 2 Department of Internal Medicine, Rutgers Health/Community Medical Center, NJ, USA
  • 3 Fatima Jinnah Medical University, Lahore, Pakistan
  • 4 Indira Gandhi Government Medical College, Nagpur, India
  • 5 Department of Internal Medicine, Trinitas Regional Medical Center, Elizabeth, NJ, USA
  • 6 Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Hospital, NY, USA
  • 7 School of Medicine, International Medical University, Kuala Lumpur, Malaysia
  • 8 Maulana Azad Medical College, New Delhi, India
  • 9 Department of Internal Medicine, Suny Upstate Medical University, NY, USA
  • 10 Henry Ford Healthcare System, Detroit, MI, USA
  • 11 General Cardiology and Advanced Heart Failure, Wellspan Cardiology, Lancaster, PA, USA
Int J Cardiol Heart Vasc, 2022 Aug;41:101073.
PMID: 35800042 DOI: 10.1016/j.ijcha.2022.101073

Abstract

BACKGROUND: Sarcoidosis is a chronic inflammatory disorder of unknown etiology associated with high morbidity and mortality. Its association with cardiovascular outcomes is under-documented.

AIM: The aim of this study was to assess the adverse cardiovascular outcomes in patients with sarcoidosis compared with that of non-sarcoidosis.

METHODOLOGY: Online databases including PubMed, Embase and Scopus were queried from inception until March 2022. The outcomes assessed included all-cause mortality (ACM) and incidence of ventricular tachycardia (VT), heart failure (HF) and atrial arrhythmias (AA).

RESULT: A total of 6 studies with 22,539,096 participants (42,763 Sarcoidosis, 22,496,354 Non-Sarcoidosis) were included in this analysis. The pooled prevalence of sarcoidosis was 13.1% (95% CI 1% to 70%). The overall mean age was 47 years. The most common comorbidities were hypertension (12.7% vs 12.5%), and diabetes mellitus (5.5% vs 4%) respectively. The pooled analysis of primary endpoints showed that all-cause mortality (RR, 2.08; 95% CI: 1.17 to 3.08; p = 0.01) was significantly increased in sarcoidosis patients. The pooled analysis of secondary endpoints showed that the incidence of VT (RR, 15.3; 95% CI: 5.39 to 43.42); p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications